Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by diffuse intraabdominal gelatinous collections with mucinous implants on the peritoneal surfaces and omentum. This condition should be considered a borderline malignancy with disease progression over time. Encouraging treatment results have been recently reported with the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods
From December 2003 to December 2010, 18 patients with PMP were referred to our institution. All patients underwent peritonectomy and CRS combined with HIPEC in accordance with Sugarbaker's procedure.
Results
The mean Peritoneal Cancer Index score was 27.6 (range, 5–39). Twelve (67%) patients had disseminated peritoneal adenomucinosis and 6 (33%) peritoneal mucinous carcinomatosis. Optimal cytoreduction with no visible residual disease or residual disease ≤2.5 mm in diameter was achieved in all patients. The mean duration of the surgical procedure including HIPEC was 9 hours and 30 minutes (range, 5–13 hours); major morbidity occurred in 30% of patients and the mortality was 11%. The mean follow-up was 27 months (range, 1–72) and the 5-year overall survival 66%.
Conclusions
In line with the existing literature, our experience suggests that patients with PMP could benefit from CRS + HIPEC in terms of survival and locoregional disease control.
SmeenkR.M., van VelthuysenM.L., VerwaalV.J., ZoetmulderF.A.: Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.Eur J Surg Oncol, 34: 196–201, 2008.
DeracoM., BarattiD., IngleseM.G., AllariaB., GavazziC., KusamuraS.: Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei.Ann Surg Oncol, 11: 393–398, 2004.
BrendanM.J., CecilT.D.: The etiology, clinical presentation and management of pseudomyxoma peritonei.Surg Oncol Clin N Am, 12: 585–603, 2003.
8.
RonnettB.M., ZahnC.M., KurmanR.J., KassM.E., SugarbakerP.H., ShmooklerB.M.: Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei”.Am J Surg Pathol, 9: 1390–1408, 1995.
9.
SzychC., StaeblerA., ConnollyD.C., WuR., ChoK.R., RonnettB.M.: Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women.Am J Pathol, 154: 1849–1855, 1999.
10.
CarrN.J., EmoryT.S., SobinL.H.: Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis and expression of p53, CD44, bcl-2.Arch Pathol Lab Med, 126: 837–841, 2002.
11.
NonakaD., KusamuraS., BarattiD, CasaliP., YounanR., DeracoM.: CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.Histopathology, 49: 381–387, 2006.
12.
ChejfecG., RiekerW.J., JablokowV.R., GouldV.E.: Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas.Gastroenterology, 90: 202–205, 1986.
13.
YanT.D., SugarbakerP.H., BrunE.A.: Pseudomyxoma peritonei from mucinous adenocarcinoma of the urachus.J Clin Oncol, 24: 4944–4946, 2006.
14.
HawesD., RobinsonR., WiraR.: Pseudomyxoma peritonei from metastatic colloid carcinoma of the breast.Gastrointest Radiol, 16: 80–82, 1991.
15.
RonnettB.M., SeidmanJ.D.: Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.Am J Surg Pathol, 27: 650–657, 2003.
16.
MisdrajiJ., YantissR.K., Graeme-CookF.M., BalisU.J., YoungR.H.: Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases.Am J Surg Pathol, 8: 1089–1103, 2003.
17.
MinerT.J., ShiaJ., JaquesD.P., KlimstraD.S., BrennanM.F., CoitD.G.: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.Ann Surg, 241: 300–308, 2004.
18.
BryantJ., CleggA.J., SidhuM.K., BrodinH., RoyleP., DavidsonP.: Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei.Health Technol Assess, 8: 1–54, 2004.
19.
YanT.D., BlackD., SavadyR., SugarbakerP.H.: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.Ann Surg Oncol, 14: 484–492, 2007.
20.
SmithJ.W., KemenyN., CaldwellC., BannerP., SigurdsonE., HuvosA.: Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience.Cancer, 70: 396–401, 1992.
21.
JessP., IversenL.H., NielsenM.B., HansenF., LaurbergS., RasmussenP.C.: Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.Dis Colon Rectum, 51: 868–874, 2008.
22.
SmeenkR.M., VerwaalV.J., AntoniniN., ZoetmulderF.A.: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Ann Surg, 245: 104–109, 2007.
23.
GunerZ., SchmidtU., DahlkeM.H., SchlittH.J., KlempnauerJ., PisoP.: Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.Int J Colorectal Dis, 20: 155–160, 2005.
24.
Van LeeuwenB.L., GrafW., PahlmanL., MahtemeH.: Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.Ann Surg Oncol, 15: 745–753, 2008.
25.
VairaM., CioppaT., DE MarcoG., BingC., D'AmicoS., D'AlessandroM., FiorentiniG., DE SimoneM.: Management of pseudomyxoma peritonei by cytoreduction + HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.In Vivo, 23: 639–644, 2009.
26.
MoranB., BarattiD., YanT.D., KusamuraS., DeracoM.: Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasm with peritoneal dissemination (pseudomyxoma peritonei).J Surg Oncol, 98: 277–282, 2008.
27.
McQuellonR., GavazziC., PisoP., SwainD., LevineE.: Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care.J Surg Oncol, 98: 300–305, 2008.
28.
SugarbakerP.H., AldermanR., EdwardsG., MarquardtC.E., GushchinV., EsquivelJ., ChangD.: Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.Ann Surg Oncol, 13: 615–644, 2006.
29.
KusamuraS., BarattiD., DeracoM.: Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.Ann Surg, 255: 238–256, 2012.
30.
SugarbakerP.H., ChangD.: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy.Ann Surg Oncol, 6: 727–731, 1999.
31.
YoussefH., NewmanC., ChandrakumaranK., MohamedF., CecilT.D., MoranB.J.: Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.Dis Colon Rectum, 54: 293–299, 2011.
